Nivalis Therapeutics Files For IPO

Boulder-based pharmaceutical developer Nivalis Therapeutics filed for an IPO this week, saying it is looking to raise up to $60M in an offering on the NASDAQ Global Market. The company says it has applied to list as NVLS. The company's IPO is being underwritten by Cowen and Company, Stifel, Baird, and H.C. Wainright & Co. Nivalis is backed by Deerfield Management, Wellington Management, Tiger Partners, RA Capital Healthcare Fund, and others. Nivalis is developing treatments for cystic fibrosis.